XENE - Xenon Pharmaceuticals Inc logo

Xenon Pharmaceuticals Inc

XENE

Xenon Pharmaceuticals develops therapeutics for neurological and psychiatric disorders, focusing on epilepsy treatments. Its key candidates include Azetukalner for seizures and pain therapies like XEN1701 and XEN1120, along with collaborations for further research.

⚕️ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago →$4,269today

Score Overview

1 Year
Score
Net Growth-18.30%
Net TrendShrank
Net Income Consistency—
Rev Growth-100.00%
Rev TrendShrank
Revenue Consistency—
5 Years
Score0.6
Net Growth-418.74%
Net TrendNever
Net Income Consistency—
Rev Growth-100.00%
Rev Trend20%
Revenue Consistency—
10 Years
Score
Net Growth-15x
Net Trend10%
Net Income Consistency
Rev Growth-100.00%
Rev Trend30%
Revenue Consistency
All Time
Score
Net Growth-31x
Net Trend8%
Net Income Consistency
Rev Growth-100.00%
Rev Trend25%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Xenon Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. XENE does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 36.50—
1 Year2025-10-22
$ 42.18-13.47%
5 Years2021-10-22
$ 30.8618.28%
10 Years2016-10-21
$ 8.55326.90%
All Time2014-11-05
$ 10.50247.62%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 409M$ 930M
2025$ 7M-$ 345M$ 548M
2024$ 0.00-$ 234M$ 626M
2023$ 0.00-$ 182M$ 638M
2022$ 9M-$ 125M$ 592M
2021$ 18M-$ 78M$ 551M
2020$ 32M-$ 28M$ 176M
2019$ 6M-$ 41M$ 141M
2018$ 0.00-$ 34M$ 119M
2017$ 311K-$ 30M$ 43M
2016$ 1M-$ 22M$ 64M
2015$ 15M-$ 15M$ 58M
IPO2014$ 28M$ 13M$ 84M
XENE - Xenon Pharmaceuticals Inc logo

Xenon Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 32M to $ 7M and net income went from -$ 28M to -$ 345M. Revenue increased in 1 of those 5 years; net income in 0.

Between 2015 and 2025, revenue declined from $ 15M to $ 7M and net income went from -$ 15M to -$ 345M. Revenue increased in 3 of those 10 years; net income in 1.

Xenon Pharmaceuticals Inc currently holds a 5-year HDB Score of 0.6 out of 10. How the HDB Score is calculated.

Membership

Explore XENE with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies